These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 31694929)

  • 1. Identification of DHODH as a therapeutic target in small cell lung cancer.
    Li L; Ng SR; Colón CI; Drapkin BJ; Hsu PP; Li Z; Nabel CS; Lewis CA; Romero R; Mercer KL; Bhutkar A; Phat S; Myers DT; Muzumdar MD; Westcott PMK; Beytagh MC; Farago AF; Vander Heiden MG; Dyson NJ; Jacks T
    Sci Transl Med; 2019 Nov; 11(517):. PubMed ID: 31694929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
    Lafita-Navarro MC; Venkateswaran N; Kilgore JA; Kanji S; Han J; Barnes S; Williams NS; Buszczak M; Burma S; Conacci-Sorrell M
    PLoS Genet; 2020 Nov; 16(11):e1009117. PubMed ID: 33201894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation.
    Mullen NJ; Shukla SK; Thakur R; Kollala SS; Wang D; Chaika N; Santana JF; Miklavcic WR; LaBreck DA; Mallareddy JR; Price DH; Natarajan A; Mehla K; Sykes DB; Hollingsworth MA; Singh PK
    Elife; 2024 Jul; 12():. PubMed ID: 38973593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer.
    Mullen NJ; Thakur R; Shukla SK; Chaika NV; Kollala SS; Wang D; He C; Fujii Y; Sharma S; Mulder SE; Sykes DB; Singh PK
    Cancer Lett; 2023 Jan; 552():215981. PubMed ID: 36341997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer.
    Guo S; Miao M; Wu Y; Pan D; Wu Q; Kang Z; Zeng J; Zhong G; Liu C; Wang J
    Oncogene; 2024 May; 43(19):1399-1410. PubMed ID: 38480915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
    Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
    Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR Screen of Druggable Targets in Small Cell Lung Cancer Identified ATM Inhibitor (AZD1390) as a Radiosensitizer.
    Ran X; Wu BX; Shi M; Song L; Nixon K; Philip V; He HH; Tsao MS; Lok BH
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1308-1314. PubMed ID: 38104868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo.
    Zameitat E; Freymark G; Dietz CD; Löffler M; Bölker M
    Appl Environ Microbiol; 2007 May; 73(10):3371-9. PubMed ID: 17369345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
    Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
    Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.
    Koundinya M; Sudhalter J; Courjaud A; Lionne B; Touyer G; Bonnet L; Menguy I; Schreiber I; Perrault C; Vougier S; Benhamou B; Zhang B; He T; Gao Q; Gee P; Simard D; Castaldi MP; Tomlinson R; Reiling S; Barrague M; Newcombe R; Cao H; Wang Y; Sun F; Murtie J; Munson M; Yang E; Harper D; Bouaboula M; Pollard J; Grepin C; Garcia-Echeverria C; Cheng H; Adrian F; Winter C; Licht S; Cornella-Taracido I; Arrebola R; Morris A
    Cell Chem Biol; 2018 Jun; 25(6):705-717.e11. PubMed ID: 29628435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis.
    He T; Haapa-Paananen S; Kaminskyy VO; Kohonen P; Fey V; Zhivotovsky B; Kallioniemi O; Perälä M
    Oncogene; 2014 Jul; 33(27):3538-49. PubMed ID: 24013224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
    Vyas VK; Ghate M
    Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
    Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Grunblatt E; Wu N; Zhang H; Liu X; Norton JP; Ohol Y; Leger P; Hiatt JB; Eastwood EC; Thomas R; Ibrahim AH; Jia D; Basom R; Eaton KD; Martins R; Houghton AM; MacPherson D
    Genes Dev; 2020 Sep; 34(17-18):1210-1226. PubMed ID: 32820040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.
    Liu Y; Li Y; Liu S; Adeegbe DO; Christensen CL; Quinn MM; Dries R; Han S; Buczkowski K; Wang X; Chen T; Gao P; Zhang H; Li F; Hammerman PS; Bradner JE; Quayle SN; Wong KK
    Cancer Res; 2018 Jul; 78(13):3709-3717. PubMed ID: 29760044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
    Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
    Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
    Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
    Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
    Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
    Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of mTOR As an Essential Kinase in SCLC.
    Kern JA; Kim J; Foster DG; Mishra R; Gardner EE; Poirier JT; Rivard C; Yu H; Finigan JH; Dowlati A; Rudin CM; Tan AC
    J Thorac Oncol; 2020 Sep; 15(9):1522-1534. PubMed ID: 32599072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.